Protective effects of taxifolin on pazopanib-induced liver toxicity: an experimental rat model-Reference-Cited by-同舟云学术

Protective effects of taxifolin on pazopanib-induced liver toxicity: an experimental rat model

Published:2021 Issue:2 Volume:70 Page:169-176
ISSN:1341-1357
Container-title:Experimental Animals
language:en
Short-container-title:Exp. Anim.

Author:

Akagunduz Baran¹,Ozer Muhammet²,Ozcıcek Fatih³,Kara Ali Veysel³,Lacın Sahin⁴,Özkaraca Mustafa⁵,Çoban Abdulkadir⁶,Suleyman Bahadır⁷,Mammadov Renad⁷,Suleyman Halis⁷

Affiliation:

1. Department of Medical Oncology, Erzincan Binali Yildirim University, Fatih Street #124, 24030, Erzincan, Turkey

2. Department of Internal Medicine, Capital Health Regional Medical Center, 750 Brunswich Avenue, 08638, Trenton, NJ, USA

3. Department of Internal Medicine, Erzincan Binali Yildirim University, Fatih Street #124, 24030, Erzincan, Turkey

4. Department of Medical Oncology, Faculty of Medicine, Yeditepe University, 326 Atasehir, 34010, Istanbul, Turkey

5. Department of Pathology, Faculty of Veterinary Medicine, Ataturk University, 12 Yakutiye Avenue, 25000, Erzurum, Turkey

6. Department of Biochemistry, Faculty of Medicine, Erzincan Binali Yildirim University, Fatih Street #124, 24030, Erzincan, Turkey

7. Department of Pharmacology, Faculty of Medicine, Erzincan Binali Yildirim University, Fatih Street #124, 24030, Erzincan, Turkey

Publisher

Japanese Association for Laboratory Animal Science

Subject

General Veterinary,General Biochemistry, Genetics and Molecular Biology,Animal Science and Zoology,General Medicine

Link

https://www.jstage.jst.go.jp/article/expanim/70/2/70_20-0103/_pdf

Reference33 articles.

1. 1. Pal SK, Hossain DMS, Zhang Q, Frankel PH, Jones JO, Carmichael C, et al.Pazopanib as third line therapy for metastatic renal cell carcinoma: clinical efficacy and temporal analysis of cytokine profile. J Urol. 2015; 193: 1114–1121.

2. 2. Endo M, Nielsen TO. Pazopanib for metastatic soft-tissue sarcoma. Lancet. 2012; 380: 801, author reply 801

3. 3. Karch A, Koch A, Grünwald V. A phase II trial comparing pazopanib with doxorubicin as first-line treatment in elderly patients with metastatic or advanced soft tissue sarcoma (EPAZ): study protocol for a randomized controlled trial. Trials. 2016; 17: 312.

4. 4. Dinkic C, Eichbaum M, Schmidt M, Grischke EM, Gebauer G, Fricke HC, et al.Pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant, recurrent, pre-treated ovarian cancer - Results of the PACOVAR-trial. Gynecol Oncol. 2017; 146: 279–284.

5. 5. Sleijfer S, Ray-Coquard I, Papai Z, Le Cesne A, Scurr M, Schöffski P, et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol. 2009; 27: 3126–3132.

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unveiling the therapeutic potential of Taxifolin in Cancer: From molecular mechanisms to immune modulation and synergistic combinations;Phytomedicine;2024-10

2. Hepatotoxicity of epidermal growth factor receptor - tyrosine kinase inhibitors (EGFR-TKIs);Drug Metabolism Reviews;2024-08-09

3. Mechanism of Action of Dihydroquercetin in the Prevention and Therapy of Experimental Liver Injury;Molecules;2024-07-27

4. Very low-carbohydrate diet with higher protein ratio improves lipid metabolism and inflammation in rats with diet-induced nonalcoholic fatty liver disease;The Journal of Nutritional Biochemistry;2024-04

5. Determination of In Vitro and In Vivo Effects of Taxifolin and Epirubicin on Epithelial–Mesenchymal Transition in Mouse Breast Cancer Cells;Technology in Cancer Research & Treatment;2024-01